Skip to content

VITAMin Insufficiency in esophagogastric Neoplasms

VITAMin Insufficiency in esophagogastric Neoplasms - VITAMIN

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50515
Enrollment
248
Registered
2021-10-06
Start date
2021-12-17
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitamin deficiency

Interventions

Two tailormade supplements for patients
one for that underwent esophagectomy and one for (sub-)total gastrectomy.

Sponsors

Zuyderland Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients >=18 years of age who underwent an esophagectomy or (sub-)total gastrectomy for malignancy with no signs of postoperative recurrence of disease.

Exclusion criteria

Exclusion criteria: - Patients that underwent a wedge resection of the stomach - Malignant disease recurrence - Metastases - Patients that are not capable to take supplementation due to altered mental status or swallow difficulties - No signed informed consent - Patients who are receiving chemotherapy - Patients with high vitamin status at baseline, except for vitamin b12

Design outcomes

Primary

MeasureTime frame
The primary endpoint is any deficiency (yes/no) defined as any of the below mentioned vitamins, minerals and proteins. The main study parameters are measurements of nutrient blood levels measured at baseline. and after 6, 12, 24 months supplementation to identify and resolve deficiencies, including: - Haemoglobin, haematocrit, MCV - Vitamins: B1, B6, B11, B12, A, D, E K - Methylmalonic acid when serum vitamin B12

Secondary

MeasureTime frame
The secondary endpoints are: -Albumin, total protein -C-reactive protein -Incidence of micronutrient deficiency post oesophageal or (sub-)total gastrectomy at baseline -Occurrence of exocrine pancreatic insufficieny (EPI) -Occurrence of the following symptoms: diarrhoea, steatorrhea, bloating which are all associated with EPI -QoL measured with questionnaires at baseline and after 6 months, 12 months and 24 months of supplementation -Vitality of patient at baseline and after 6 months, 12 months and 24 months of supplementation

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)